In vitro & In-vivo Cytotoxic Evaluation of Magneto-Electric Nanoparticles for the CNS Delivery
Our laboratory has explored potentials of magneto-electric nanoparticles (MENPs) as in-vitro on-demand controlled release of drugs for the treatment of neuroAIDS and other CNS diseases. Aim of this research was to explore cytotoxicity of MENP nanoformulation both in vitro & in vivo. In this work, we have explored the dose dependent (50-250 µg/mL) in vitro and in vivo cytotoxicity (5-20 mg/kg) of MENPs of BaTiO3@CoF2O4 in primary brain cells (neurons & astrocytes) and Balb/C mice to assess general and organ specific cytotoxicity, respectively. Biocompatibility results showed that treatments with different concentrations of MENP nanoformulation do not show any sign of cytotoxicity and the percentage of viable cells (> 90%) was similar to untreated control. Further, pilot in vivo studies with Balb/C mice were performed for MENP dose optimization, a dose of 10mg/kg showed the best result. Further, organ specific (brain, kidney, liver and spleen) and peripheral blood parameters (Hepatic and renal function test) toxicity were tested using standard H&E staining method and blood profiling method respectively. In conclusion, we can say that results suggest that doses of MENPs nanoformulation are nontoxic and have no significant safety concerns. Thus, suggesting potential application of MENPs for site-specific on-demand controlled delivery of therapeutics across BBB for the prevention CNS diseases.